---
title: "Follow-up rates and predictors after “Possible AF” alerts from a home ECG monitor in older adults"
id: "plos-one-19-rates-and-predictors-of-hospital-visits-after-possible-af-alerts-from-a-home"
canonical_url: "https://medichelpline.com/clinical-feed/plos-one-19-rates-and-predictors-of-hospital-visits-after-possible-af-alerts-from-a-home"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "PLOS ONE (Medicine)"
source_url: "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0353867"
published_at: "2026-07-17T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Follow-up rates and predictors after “Possible AF” alerts from a home ECG monitor in older adults
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-one-19-rates-and-predictors-of-hospital-visits-after-possible-af-alerts-from-a-home
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** PLOS ONE (Medicine)
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0353867)
- **Published At:** 2026-07-17T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- This sub-analysis of the **Omron Heart Study** evaluated healthcare-seeking behavior after device-displayed **“possible AF”** alerts in 3,820 hypertensive participants aged ≥60 years who used a home blood pressure monitor with a 30-second single-lead **ECG** twice daily for 3 months. - Of 1,700 participants who received ≥1 **possible AF** notification, 399 (23.5%) reported visiting a healthcare facility within 3 months and 289 (17.0%) underwent additional testing; 35 (2.1%) reported an AF diagnosis by 3 months and 115 (52.3% of adjudicated AF) had a clinical AF diagnosis by 12 months. - Physician adjudication of all flagged tracings confirmed AF in 220 of 1,700 alerted participants (12.9%); 87% of device alerts were not adjudicated as AF. - Among 175 participants with valid visit dates, median time from first alert to medical visit was 28 days (mean 36.4 days). - Multivariable analysis identified lower odds of visiting a healthcare facility for participants aged <65 years (OR 0.75), current drinkers (OR 0.73), those without daily palpitations (OR 0.69), and those without palpitations on the alert day (OR 0.51). - Device-extrinsic factors: greater number of detections on the first alert day (OR 1.25 per additional detection) and detection on 2 consecutive days (OR 2.22) were associated with higher odds of visiting within 3 months; neither frequency metric was associated with time to visit. - The study used a decentralized recruitment strategy (OMRON Connect app and website), blinded physician ECG adjudication after the recording period, and questionnaires at 3 and 12 months; no active clinical follow-up or alert confirmation was provided to participants. - Findings highlight a substantial gap between mHealth alert generation and subsequent clinical action, with low follow-up despite device advisories to consult a physician and a sizable proportion of adjudicated AF cases remaining undiagnosed in clinical care at 12 months.
## Clinical Analysis & Structured Key Points
SKIP TO MAIN CONTENT Advertisement plos.org Create account Sign in About Browse Publish advanced search 0 Save 0 Citation 9 View 0 Share OPEN ACCESS PEER-REVIEWED RESEARCH ARTICLE Rates and predictors of hospital visits after “Possible AF” alerts from a home ECG monitor in older adults with hypertension: A sub-analysis of the Omron Heart Study Yusuke Kakei, Keitaro Senoo , Arito Yukawa, Kohei Kawai, Masahiro Makino, Jun Munakata, Nobunari Tomura, Satoshi Shimoo, Hirokazu Shiraishi, Satoaki Matoba Published: July 17, 2026 https://doi.org/10.1371/journal.pone.0353867 Article Authors Metrics Comments Media Coverage Peer Review Abstract Introduction Methods Results Discussion Conclusion Supporting information Acknowledgments References Reader Comments Figures Abstract Background Home ECG can detect atrial fibrillation (AF), but patients’ hospital visit behavior after “possible AF” alerts remains uncertain. We assessed the rates, timing, and correlates of hospital visits following “possible AF” alerts in older adults with hypertension. Methods and findings In a nationwide, decentralized cohort in Japan, 4,078 individuals aged ≥60 years enrolled; 3,820 were analyzed after exclusions. Participants used a home BP monitor equipped with a 30-s single-lead ECG capable of detecting “possible AF”, twice daily for 3 months. Of 1,700 participants who received ≥1 “possible AF” alert, 399 (23.5%) reported an alert-prompted healthcare facility visit within 3 months, and 289 (17.0%) underwent additional testing. Among 175 participants with valid visit dates, the median time to visit was 28 days (mean 36.4). In multivariable models, factors associated with lower odds of a hospital visit included age < 65 years (OR 0.75, 95% CI 0.59–0.95, p = 0.016), current drinking (OR 0.73, 0.57–0.95, p = 0.018), no daily palpitations (OR 0.69, 0.50–0.95, p = 0.022), and no palpitations on the alert day (OR 0.51, 0.30–0.85, p = 0.010). Notably, 105 of 220 (47.7%) participants with physician-adjudicated AF remained without a clinical diagnosis at 12 months. Conclusions In this cohort of older, hypertensive individuals, follow-up rates after a “possible AF” alert were low; fewer than one in four individuals visited a healthcare facility, and fewer than one in five underwent additional testing within 3 months. Hospital visits were less common among younger participants, those who consume alcohol, and those without palpitations. These findings highlight significant gaps between mHealth alerts and subsequent clinical action. Figures Citation: Kakei Y, Senoo K, Yukawa A, Kawai K, Makino M, Munakata J, et al. (2026) Rates and predictors of hospital visits after “Possible AF” alerts from a home ECG monitor in older adults with hypertension: A sub-analysis of the Omron Heart Study. PLoS One 21(7): e0353867. https://doi.org/10.1371/journal.pone.0353867 Editor: Daniel Antwi-Amoabeng, Christus Oschner St. Patrick Hospital, UNITED STATES OF AMERICA Received: December 12, 2025; Accepted: June 30, 2026; Published: July 17, 2026 Copyright: © 2026 Kakei et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability: The data underlying this study cannot be shared publicly because they contain potentially identifying participant information (age, sex, prefecture of residence, and medical history) that could compromise participant privacy. These restrictions were imposed by the Ethics Review Board of Kyoto Prefectural University of Medicine (approval No. ERB-C-1994). De-identified data may be made available upon reasonable request, subject to review in accordance with the ethical approval and participant consent requirements. Data access requests should be directed to the Department of Cardiac Arrhythmia Research and Innovation, Graduate School of Medical Science, Kyoto Prefectural University of Medicine (465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan; Email: artma@koto.kpu-m.ac.jp). Funding: The author(s) received no specific funding for this work. Competing interests: The authors have declared that no competing interests exist. Introduction The prevalence of atrial fibrillation (AF) and associated stroke is increasing with the progressive aging of the population. Early rhythm control strategies and catheter ablation have been reported as effective treatments for AF [1–3], highlighting the growing importance of early detection and intervention. In recent years, home-use devices equipped with AF detection capabilities, such as home electrocardiogram (ECG) monitors, have become widespread. One such example is the Complete (Omron Healthcare, Kyoto, Japan), a home blood pressure monitor with ECG functionality. It enables simultaneous blood pressure (BP) measurement and ECG recording and is utilized in various settings [4–6]. While home ECG monitoring devices equipped with algorithms capable of detecting rhythm irregularities suggestive of AF have become increasingly available, the subsequent rate of consultation with medical institutions following screening remains notably low. In fact, the AF-CATCH study, which used ECG screening, reported that among 103 individuals diagnosed with AF, only 17 consulted a specialist within one year [7]. Furthermore, follow-up rates in screening studies using photoplethysmography (PPG) were also modest: 57% in the Apple Heart Study, 35.3% in the Fitbit Heart Study, and 61.8% in the Huawei Heart Study. [8–10] Thus, low follow-up rates after suspected AF detection appear to be a common issue, regardless of the screening modality (ECG or PPG). Recent large-scale randomized trials, including the VITAL-AF and GUARD-AF studies, have further demonstrated that while systematic screening can identify new AF cases, the clinical pathway from detection to treatment initiation remains challenging [11–13]. However, the factors that hinder patients from seeking medical consultation after screening are not well understood. Therefore, this study investigated healthcare-seeking behaviors following AF screening as a sub-analysis of the Omron Heart Study, an AF screening trial targeting hypertensive patients aged 60 years or older. The Omron Heart Study was a prospective, multicenter observational study conducted across Japan from April 2022 to July 2023, which enrolled 4,078 hypertensive patients aged 60 years or older to evaluate home-based ECG and blood pressure monitoring for AF screening. Methods To include a geographically and demographically diverse population, we enrolled participants using a decentralized clinical trial (DCT) approach. During the enrollment period, we invited users of the OMRON Connect smartphone application (Omron Healthcare Co., Ltd., Kyoto) via in-app notifications. OMRON Connect is a health-management app provided by Omron Healthcare that enables seamless transfer and management of data from Omron blood pressure monitors, body composition scales, and pedometers via Bluetooth. To avoid restricting recruitment to technology-savvy users, we additionally recruited volunteers aged ≥60 years who did not use OMRON Connect via a study website. Participants reviewed study information on the website and were directed to an online application. Eligibility was screened online; those deemed eligible provided electronic informed consent on the website. The study office then mailed a Complete device to each enrolled participant. Participants recorded ECGs and blood pressure for 3 months after receipt of the device. The protocol was approved by the Ethics Review Board of Kyoto Prefectural University of Medicine (approval No. ERB-C-1994). The dataset used for this secondary analysis was accessed for research purposes on 21 June 2024. During the data collection process, the authors had access to information that could identify individual participants, but only for research purposes and in accordance with ethical standards. Any information that could directly identify individual participants was not used in the analysis and was safeguarded to ensure confidentiality in line with privacy requirements. Eligibility Inclusion criteria were: (1) a history of hypertension treated with antihypertensive medication; (2) age ≥ 60 years; and (3) provision of informed consent. Exclusion criteria were: (1) current participation in, or plans to participate in, an interventional trial; (2) self-reported prior physician-diagnosed AF; (3) self-reported use of oral anticoagulation; (4) implanted pacemaker and/or defibrillator; (5) residence outside Japan; and (6) any condition judged by the treating physician to make participation inappropriate. Device use and follow-up Participants were instructed to obtain two measurements each morning and evening by touching the electrodes on the top and both sides of the Complete monitor, thereby recording a 30-second ECG concurrently with BP measurement, for a period of 3 months. All participants were instructed to sit with feet flat on the floor for 5 minutes before measurement and to allow a 30-second interval between the two measurements; the average of the two readings was used. During ECG recording with the Complete monitor, the OMRON connect smartphone application served as the display. When the algorithm detected a rhythm consistent with possible AF, the application showed a “possible AF” result. The alert indicated “possible atrial fibrillation” and advised the user to consult a physician. No active monitoring service or follow-up system was implemented to contact participants after receiving an alert. No specific reminder or follow-up was provided to participants who did not seek medical advice after receiving an alert, as the study was designed as an observational investigation of natural healthcare-seeking behavior. A dedicated monitoring server tracked device usage and handled participant inquiries throughout follow-up. Each week, participants automatically received an email report from the study office summarizing their ECG measurement adherence for that week and the remaining days until study end. If adherence was 0% for three consecutive days, call-center staff telephoned the participant to check for device malfunction. At 3 months after enrollment, participants completed a questionnaire regarding care-seeking during the 3-month period; devices and questionnaires were returned to the study office. The 3-month questionnaire assessed whether participants had visited a healthcare facility in response to the device alert, whether additional testing had been recommended, whether they had received a new AF diagnosis, and whether anticoagulation therapy had been initiated. The questionnaire also inquired about palpitations both at the time of the alert and in daily life. The full questionnaire is provided as Supplementary Material (S1 Questionnaire). At 12 months after enrollment, participants completed a second questionnaire focusing on physician-diagnosed AF and subsequent clinical management. ECG adjudication After the 3-month recording window, each 30-second ECG tracing was independently reviewed, under blinding, by six board-certified cardiologists. Tracings flagged as possible AF by the device were categorized as sinus rhythm, AF, or uninterpretable. For each tracing, three cardiologists were randomly assigned; AF was confirmed only when at least two of the three adjudications indicated AF. When the three readings were discordant, the tracing was reread and a consensus was reached through discussion. The ECG adjudication was performed after the 3-month recording period had ended, and the results were not communicated to participants. Therefore, participants’ healthcare-seeking behavior was based solely on the device alerts and their own initiative to seek care. Outcomes and statistical analysis Baseline characteristics and questionnaire responses were summarized as counts (percentages) for categorical variables and mean (standard deviation) for continuous variables. Univariable and multivariable logistic regression analyses were used to examine factors associated with hospital visits. Patient-intrinsic baseline characteristics were analyzed using multivariable logistic regression, while device-extrinsic factors (e.g., alert frequency) were analyzed separately using univariable analyses to maintain clarity of interpretation. The time from the device AF alert to the first medical visit was modeled using Poisson regression to estimate incidence rate ratios (IRRs). Negative binomial regression was used when overdispersion was present. The Mann–Whitney U test was used as a non-parametric test to compare distributions between groups. A two-sided p-value < 0.05 was considered statistically significant. Analyses were performed using R (version 4.4.1), and results are presented as odds ratios (ORs) with 95% confidence intervals (CIs) and IRRs. Of the 399 participants who reported visiting a hospital within 3 months, 175 provided valid visit dates (i.e., dates within the 3-month observation period). The remaining 224 participants either did not provide a specific date or reported dates outside the observation window. The time-to-visit analysis (including Poisson/negative binomial regression and Mann–Whitney U tests) was limited to these 175 participants with valid visit dates. Results Study population From April 2022 through July 2023, 4,078 individuals with hypertension across Japan enrolled. Of these, 2,182 (53.5%) were recruited through the OMRON connect smartphone application and 1,896 (46.5%) through a website. After excluding 258 for insufficient measurement data, 3,820 participants were analyzed. During the 3-month measurement period, 1,700 participants had at least one “possible AF” notification by the device (Fig 1). Physician adjudication of ECG waveforms confirmed AF in 220 participants. Of the 220 participants with physician-adjudicated AF, 218 (99.1%) responded to the 3-month follow-up questionnaire and 176 (80.0%) responded to the 12-month follow-up questionnaire. Baseline characteristics of the 1,700 participants with a possible AF notification are shown in Table 1. Download: PNG larger image TIFF original image Table 1. Baseline characteristics of participants with “possible AF”. https://doi.org/10.1371/journal.pone.0353867.t001 Download: PNG larger image TIFF original image Fig 1. Schematic for study. Figure legend: Adults with hypertension aged ≥60 years were recruited nationwide (April 2022–July 2023). Participants used a home blood pressure monitor equipped with a single-lead electrocardiogram (ECG) (Complete; Omron Healthcare, Kyoto, Japan) to record blood pressure and a 30 s ECG twice daily for 3 months. Of 4,078 enrollees, 258 were excluded for absence of any measurements, leaving 3,820 in the analysis set. During the recording window, 1,700 participants received at least one device-generated “possible AF” notification. Abbreviations: AF, atrial fibrillation; ECG, electrocardiogram. https://doi.org/10.1371/journal.pone.0353867.g001 Questionnaire responses at 3 and 12 months Questionnaire results at 3 and 12 months are summarized in Table 2. At 3 months, we obtained questionnaire responses from 1,682 participants (98.9%); at 12 months, from 1,323 (77.8%). At 3 months, 399 participants (23.5%) reported visiting a healthcare facility in response to the device display. Additional testing had been performed in 289 (17.0%); 35 (2.1%) had been diagnosed with AF; and 18 (1.1%) had initiated anticoagulation. Between 3 and 12 months, an additional 80 participants (4.7%) reported a new AF diagnosis, 10 (0.6%) initiated anticoagulation, 2 (0.1%) underwent electrical cardioversion, and 14 (0.8%) underwent catheter ablation. Altogether, 115 participants had an AF diagnosis in clinical care within 12 months, corresponding to 52.3% of the 220 adjudicated as AF by physician review. Download: PNG larger image TIFF original image Table 2. 3-month and 12-month surveys of possible AF detected patients. https://doi.org/10.1371/journal.pone.0353867.t002 Factors associated with hospital visits In multivariable logistic regression with the outcome of a medical visit within 3 months, age < 65 years, current alcohol use, absence of palpitations at the time of the device alert, and absence of palpitations in daily life were each associated with significantly lower odds of visiting a healthcare facility. Specifically, participants without palpitations on the alert day were approximately half as likely to visit a healthcare facility (OR 0.51), and those without daily palpitations were also less likely to seek care (OR 0.69). Participants aged <65 years were approximately 25% less likely to visit (OR 0.75), and current drinkers were approximately 27% less likely (OR 0.73). In the three-level smoking history comparison (current, former, none), using never-smoking as the reference, past smoking was significantly associated with visiting a healthcare facility (Table 3). We evaluated interactions among key variables; none were both statistically significant and clinically interpretable. Among the 175 participants with valid visit dates, the mean and median times from the first device alert to the medical visit were 36.4 and 28 days, respectively. No candidate covariate showed a significant association with time to visit. Download: PNG larger image TIFF original image Table 3. Logistic regression for factors associated with a hospital visit. https://doi.org/10.1371/journal.pone.0353867.t003 Association between alert frequency and hospital visits We also examined the relationship between the number of “possible AF” detections and hospital visit. A greater number of possible AF detections on the first alert day was associated with higher odds of visiting within 3 months (OR 1.25, 95% CI 1.09–1.42, p = 0.0009). In contrast, the association with time to visit was not significant (IRR 0.95, 95% CI 0.85–1.06, p = 0.34). When possible AF was displayed on 2 consecutive days, visiting within 3 months was more likely (OR 2.22, 95% CI 1.62–3.04, p < 0.001), whereas the association with time to visit was not significant (IRR 0.82, 95% CI 0.58–1.18, p = 0.29). Discussion In our follow-up investigation, despite receiving a “possible AF” notification from the home device, only 399 patients (23.5%) visited a medical institution specifically in response to the alert within 3 months. Additional diagnostic testing was performed in only 289 patients (17.0%). The median time to consultation was approximately one month. Notably, the Omron Heart Study cohort, from which our sample was drawn, was recruited from “OMRON Connect” app users and volunteers, potentially representing a population with relatively high health consciousness. This selection bias suggests that the consultation rate in a real-world, general consumer setting might be even lower. It is important to note that only 220 of 1,700 participants (12.9%) who received “possible AF” alerts were confirmed to have AF by physician adjudication, meaning that approximately 87% of alerts were not confirmed as AF. This high rate of unconfirmed alerts provides critical context for interpreting the observed low follow-up rate of 23.5%. The decision not to seek medical care after receiving an alert may, in part, represent a reasonable response, particularly among participants who received only a single alert. It should be emphasized that the behavioral analysis in this study examines responses to “possible AF” alerts from the device, not confirmed AF episodes. Future digital health interventions should consider strategies to improve the positive predictive value of alerts to enhance appropriate healthcare-seeking behavior. The effectiveness of cardiovascular screening programs has long been challenged by low adherenc
## Related Clinical Research

- [Sacubitril/valsartan after AFib ablation tied to lower recurrence vs valsartan alone](https://medichelpline.com/clinical-feed/aha-news-1-blood-pressure-medication-combo-linked-to-fewer-irregular-heart-rhythms-after.md)
- [Switching to ARNI Associated with Lower Short-Term New-Onset Atrial Fibrillation in HFrEF](https://medichelpline.com/clinical-feed/pubmed-42740677.md) (DOI: 10.1093/ehjcvp/pvag074)
- [GLP-1 drugs tied to lower diabetes progression and cardiovascular events than metformin](https://medichelpline.com/clinical-feed/aha-news-4-glp-1-meds-linked-to-lower-diabetes-heart-risks-than-standard-diabetes.md)
- [Comparing BMI, Waist Circumference, and BRI for Predicting ASCVD, AF, and Mortality in 1.2M Koreans](https://medichelpline.com/clinical-feed/plos-one-14-prognostic-associations-of-anthropometric-indices-with-major-health-outcomes-a.md)
- [Rising stroke incidence in adults under 55 despite overall declines in the US](https://medichelpline.com/clinical-feed/medical-news-today-0-stroke-rates-are-falling-overall-but-rising-among-adults-under-55.md)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.